Abstract：
The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC.
To present a summary of the 2022 RCC guideline, which is based on a standardised methodology including systematic reviews (SRs) and provides transparent and reliable evidence for the management of RCC.
For the 2022 update, a new literature search was carried out with a cutoff date of May 28, 2021, covering the Medline, EMBASE, and Cochrane databases. The data search focused on randomised controlled trials (RCTs) and retrospective or controlled comparator-arm studies, SRs, and meta-analyses. Evidence synthesis was conducted using modified GRADE criteria as outlined for all the EAU guidelines.
All chapters of the RCC guideline were updated on the basis of a structured literature assessment, and clinical practice recommendations were developed. The majority of the studies included were retrospective with matched or unmatched cohorts and were based on single- or multi-institution data or national registries. The exception was systemic treatment of metastatic RCC, for which there are several large RCTs, resulting in recommendations that are based on higher levels of evidence.
The 2022 RCC guidelines have been updated by a multidisciplinary panel of experts using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2022.
The European Association of Urology panel for guidelines on kidney cancer has thoroughly evaluated the research data available to establish up-to-date international standards for the care of patients with kidney cancer.
To present a summary of the 2022 RCC guideline, which is based on a standardised methodology including systematic reviews (SRs) and provides transparent and reliable evidence for the management of RCC.
For the 2022 update, a new literature search was carried out with a cutoff date of May 28, 2021, covering the Medline, EMBASE, and Cochrane databases. The data search focused on randomised controlled trials (RCTs) and retrospective or controlled comparator-arm studies, SRs, and meta-analyses. Evidence synthesis was conducted using modified GRADE criteria as outlined for all the EAU guidelines.
All chapters of the RCC guideline were updated on the basis of a structured literature assessment, and clinical practice recommendations were developed. The majority of the studies included were retrospective with matched or unmatched cohorts and were based on single- or multi-institution data or national registries. The exception was systemic treatment of metastatic RCC, for which there are several large RCTs, resulting in recommendations that are based on higher levels of evidence.
The 2022 RCC guidelines have been updated by a multidisciplinary panel of experts using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2022.
The European Association of Urology panel for guidelines on kidney cancer has thoroughly evaluated the research data available to establish up-to-date international standards for the care of patients with kidney cancer.
摘要：
欧洲泌尿外科协会（EAU）肾细胞癌（RCC）指南小组为RCC的管理制定了基于证据的指南和建议。
为了介绍2022年碾压混凝土指南的摘要，该方法基于包括系统评价（SRs）在内的标准化方法，并为RCC的管理提供透明可靠的证据。
对于2022年更新，进行了一项新的文献检索，截止日期为2021年5月28日，涵盖了Medline，EMBASE,和Cochrane数据库。数据搜索集中在随机对照试验（RCT）和回顾性或对照比较组研究，SRs,和荟萃分析。使用所有EAU指南概述的修改的GRADE标准进行证据综合。
在结构化文献评估的基础上更新了RCC指南的所有章节。并制定了临床实践建议。纳入的大多数研究都是回顾性的，有匹配或不匹配的队列，并且基于单或多机构数据或国家注册。转移性肾癌的全身治疗是例外，有几个大型的RCT，从而得出基于更高水平证据的建议。
2022年RCC指南已由多学科专家小组使用最高的方法学标准进行了更新。这些指南为2022年RCC的管理提供了最可靠的当代证据基础。
欧洲泌尿外科协会肾癌指南小组已经全面评估了现有的研究数据，以建立最新的肾癌患者护理国际标准。
为了介绍2022年碾压混凝土指南的摘要，该方法基于包括系统评价（SRs）在内的标准化方法，并为RCC的管理提供透明可靠的证据。
对于2022年更新，进行了一项新的文献检索，截止日期为2021年5月28日，涵盖了Medline，EMBASE,和Cochrane数据库。数据搜索集中在随机对照试验（RCT）和回顾性或对照比较组研究，SRs,和荟萃分析。使用所有EAU指南概述的修改的GRADE标准进行证据综合。
在结构化文献评估的基础上更新了RCC指南的所有章节。并制定了临床实践建议。纳入的大多数研究都是回顾性的，有匹配或不匹配的队列，并且基于单或多机构数据或国家注册。转移性肾癌的全身治疗是例外，有几个大型的RCT，从而得出基于更高水平证据的建议。
2022年RCC指南已由多学科专家小组使用最高的方法学标准进行了更新。这些指南为2022年RCC的管理提供了最可靠的当代证据基础。
欧洲泌尿外科协会肾癌指南小组已经全面评估了现有的研究数据，以建立最新的肾癌患者护理国际标准。
